Monte Rosa Therapeutics, Inc. (GLUE) Market Cap & Valuation Ratios
Monte Rosa Therapeutics, Inc. (GLUE) has a market cap of $924.8M and a price-to-sales ratio of 32.2, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GLUEMonte Rosa Therapeutics, Inc.Follow GLUE — free
—
Price chart with a free account
- Market cap
- 924.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| GLUE | 0.9 | — | 29.1 | — | -3.5% | -84% | — | -61% |
| JBIO | 0.9 | — | — | — | -13.3% | — | — | -50% |
| CGEM | 0.9 | — | — | — | — | — | — | -67% |
| VSTM | 0.9 | — | 9.7 | — | — | +3996% | -183% | — |
| RIGL | 0.9 | — | 3.0 | 9.4 | 8.8% | +3% | 31% | 17% |
| CRVS | 0.9 | — | — | — | -5.1% | — | — | -42% |
| MGTX | 0.9 | 11.0 | 2.1 | 4.3 | 1.2% | +948% | 46% | 165% |
| ALMS | 0.9 | — | 110.0 | — | — | — | — | -127% |
| AKTS | 0.9 | — | — | — | — | — | — | — |
| SVRA | 0.9 | — | — | — | -12.8% | — | — | -109% |
| ANRO | 0.9 | — | — | — | -8.0% | — | — | — |
| Median of these 10 | 11.0 | 6.4 | 6.8 | -6.5% | +948% | 31% | -50% |
; EV/Sales 29.1 vs. 6.4.
Growth vs. price
each dot a company · hover or tap for valuesMonte Rosa Therapeutics, Inc. — questions
- What is Monte Rosa Therapeutics, Inc.'s market cap?
- $924.8M.
- What is Monte Rosa Therapeutics, Inc.'s price-to-sales ratio?
- 32.2.
Every figure on this page comes from Monte Rosa Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.